{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T07:00:25Z","timestamp":1780902025440,"version":"3.54.1"},"reference-count":14,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Isolated Locoregionally Recurrent Pancreatic Adenocarcinoma (ILRPA) accounts for 25\u201330% of recurrences after radical resection, yet the role of salvage radiation (RT) in this setting remains controversial due to limited data. We aimed to evaluate the impact of salvage RT on survival outcomes compared with non-salvage RT in patients with ILRPA. We retrospectively analyzed data of patients with ILRPA post-radical resection treated at our centre between 2012 and 2021. Patients were categorized into two cohorts based on whether salvage RT was administered post-recurrence. Patients who received a minimum of 30 Gy in 10 fractions (BED10 \u2265 39 Gy) were included for analysis. The clinical characteristics, treatments, and outcomes were analyzed. The chi-square or Fisher\u2019s exact test for categorical variables and Student\u2019s t-test or Wilcoxon rank sum test for continuous variables were utilized for comparisons. The Kaplan\u2013Meier method and log-rank test were performed to compare overall survival (OS) and progression-free survival (PFS) between the two groups. OS and PFS were calculated from the time of locoregional recurrence until event or loss of follow-up. Thirty-two patients were identified, with sixteen patients in each group. The patients and tumour characteristics were balanced between the two cohorts, except for chemotherapy, where the salvage RT group tended to receive palliative chemotherapy more than the non-salvage group (p = 0.007). The median radiotherapy dose received for the salvage RT cohort was 50.4 Gy (BED10 = 59.5 Gy). Chemotherapy was restarted in 75% either before, after, or during radiation, and only in 31.25% of patients in the non-salvage group (p = 0.013). Patients who received salvage RT had statistically significantly better median OS and PFS than those who did not (25.2 vs. 8.4 months, p = 0.0006, HR 0.25, 95% CI (0.11\u20130.59)), (15.6 vs. 7.2 months, p = 0.0006, HR 0.26, 95% CI (0.11\u20130.58), respectively). Ten patients (62.5%) developed distant metastases (DM) at least 3 months post-recurrence in the salvage RT cohort compared to five patients (31.25%) in the non-salvage RT cohort (p = 0.08). In the salvage RT group, 10\/16 patients (62.5%) maintained locoregional disease control post-RT. Salvage RT was associated with better OS and PFS in patients with ILRPA, highlighting its potential as an essential treatment modality. While salvage RT appears beneficial, confounding factors like chemotherapy disparities between groups necessitate further investigation in prospective cohorts.<\/jats:p>","DOI":"10.3390\/curroncol33060337","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:43:46Z","timestamp":1780897426000},"page":"337","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salvage Radiotherapy in Isolated Locoregional Recurrence of Pancreatic Adenocarcinoma Post-Radical Surgical Resection: Prudent or Pointless? A Retrospective Comparative Analysis"],"prefix":"10.3390","volume":"33","author":[{"given":"Colin","family":"Faulkner","sequence":"first","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-3182","authenticated-orcid":false,"given":"Ayah","family":"Erjan","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman 11941, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mheid","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman 11941, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Yan","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaya Ganor","family":"Shwaartz","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Tsang","sequence":"additional","affiliation":[{"name":"Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeetha","family":"Kalimuthu","sequence":"additional","affiliation":[{"name":"Laboratory Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodor","family":"Stanescu","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hosni","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-794X","authenticated-orcid":false,"given":"Aruz","family":"Mesci","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00066-014-0610-8","article-title":"Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis","volume":"190","author":"Nakamura","year":"2014","journal-title":"Strahlenther. Onkol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.21.01220","article-title":"Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma","volume":"39","author":"Hall","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dee, E.C., Ng, V.C., O\u2019reilly, E.M., Wei, A.C., Lobaugh, S.M., Varghese, A.M., Zinovoy, M., Romesser, P.B., Wu, A.J., and Hajj, C. (2024). Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery. J. Clin. Med., 13.","DOI":"10.3390\/jcm13092631"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.hpb.2016.11.001","article-title":"Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT","volume":"19","author":"Groot","year":"2017","journal-title":"HPB"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Serafini, S., Sperti, C., Friziero, A., Brazzale, A.R., Buratin, A., Ponzoni, A., and Moletta, L. (2021). Systematic Review and Meta-Analysis of Surgical Treatment for Isolated Local Recurrence of Pancreatic Cancer. Cancers, 13.","DOI":"10.3390\/cancers13061277"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ejso.2016.12.012","article-title":"Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study","volume":"43","author":"Comito","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.21037\/jgo-22-38","article-title":"Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection","volume":"13","author":"Reddy","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_9","first-page":"34","article-title":"Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer","volume":"7","author":"Wilkowski","year":"2006","journal-title":"J. Pancreas"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1016\/j.ijrobp.2024.07.978","article-title":"2974 Salvage Radiotherapy in Isolated Locoregional Recurrence of Pancreatic Adenocarcinoma Post-Radical Surgical Resection: Prudent or Pointless? A Retrospective Comparative Analysis","volume":"120","author":"Erjan","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1748-717X-8-27","article-title":"Chemoradiation in patients with isolated recurrent pancreatic cancer\u2014Therapeutical efficacy and probability of re-resection","volume":"8","author":"Habermehl","year":"2013","journal-title":"Radiat. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.ijrobp.2021.07.408","article-title":"SBRT for the Treatment of Isolated Local Recurrence of Resected Pancreatic Cancer","volume":"111","author":"Morris","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Physics."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00432-012-1165-7","article-title":"Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: Predictors and implications for adjuvant chemoradiotherapy","volume":"138","author":"Zhang","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2024.10.026","article-title":"NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy","volume":"121","author":"Sanford","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/337\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:42:00Z","timestamp":1780900920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["curroncol33060337"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33060337","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]}}}